San Diego-based Amylin Pharmaceuticals (Nasdaq: AMLN) has cut 60 jobs, or about 4 percent of its workforce, according to a recent story in the Union-Tribune. The cuts happened within a few specific areas of the company, including R&D, spokeswoman Anne Erickson said. "The R&D changes do not signal a move away from research at Amylin," Erickson said in an email. "Rather, we are changing how we source innovation and will look to both internal and external sources to find ways to continue to fulfill our mission of bringing innovative medicines to patients."
Luke Timmerman is the National Biotechnology Editor for Xconomy, and the Editor of Xconomy Seattle. You can email him at firstname.lastname@example.org, or call 206-624-2374.